SAT0465 An integrated safety data analysis across all phase ii and phase iii clinical programs for ustekinumab in psoriatic arthritis, crohn's disease, and psoriasis

Abstract

ObjectivesTherapeutic decisions are based on efficacy, but clinicians need to consider medication safety in this process. Here, we report ustekinumab (UST) integrated safety data in patients (pts) with psoriatic arthritis...